


## **Supplementary information**

### **Tubular iron deposition and iron handling proteins in human healthy kidney and chronic kidney disease**

Sanne van Raaij MSc<sup>1</sup>, Rachel van Swelm PhD<sup>1</sup>, Karlijn Bouman BSc<sup>1</sup>, Maaïke Cliteur BSc<sup>1</sup>, Marius van den Heuvel MD, PhD<sup>2,3</sup>, Jeanne Pertijs BSc<sup>4</sup>, Dominic Patel MSc<sup>5</sup>, Paul Bass MD<sup>6,7</sup>, Harry van Goor MD, PhD<sup>2</sup>, Robert Unwin MD, PhD<sup>6,8</sup>, Surjit Kaila Srail PhD<sup>9#\*</sup>, Dorine Swinkels MD, PhD<sup>1#\*</sup>


<sup>1</sup>Department of Laboratory Medicine, Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen, the Netherlands; <sup>2</sup>Department of Pathology and Medical Biology, University Medical Center Groningen and University of Groningen, Groningen, the Netherlands; <sup>3</sup>Pathologie Friesland, Leeuwarden, the Netherlands; <sup>4</sup>Department of Pharmacology and Toxicology, Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen, the Netherlands; <sup>5</sup>Research Department of Pathology, UCL Cancer Institute, University College London, London, United Kingdom; <sup>6</sup>UCL Centre for Nephrology, Royal Free Hospital, London, United Kingdom; <sup>7</sup>Department of Cellular Pathology, Royal Free Hospital, London, United Kingdom; <sup>8</sup>Cardiovascular and Metabolic Diseases iMED ECD, AstraZeneca, Gothenburg, Sweden; <sup>9</sup>Department of Structural & Molecular Biology, Division of Biosciences, University College London, London, United Kingdom; #contributed equally, \*corresponding author.

Corresponding author: Dorine Swinkels, MD, PhD, [Dorine.Swinkels@Radboudumc.nl](mailto:Dorine.Swinkels@Radboudumc.nl), and Surjit Kaila Srail, PhD, [k.srail@ucl.ac.uk](mailto:k.srail@ucl.ac.uk).



**Supplementary Figure 1: Primary antibody control stainings**

Representative images of primary antibody control (primary antibody replaced by IgG control) for staining procedure of ZIP8 (a), ZIP14 (b), divalent metal transporter 1 (DMT1; c), L-ferritin (d), H-ferritin (e), ferroportin (f) and heme oxygenase-1 (HO-1; g). Renal structures indicated as glomerulus (G), proximal tubule (PT), and distal tubule (DT). Scale bar 20  $\mu$ M.



**Supplementary Figure 2: Secondary antibody control stainings**

Representative images of secondary antibody control (omission of primary antibody) for staining procedure of ZIP8 (a), ZIP14 (b), divalent metal transporter 1 (DMT1; c), L-ferritin (d), H-ferritin (e), ferroportin (f) and heme oxygenase-1 (HO-1; g). Renal structures indicated as glomerulus (G), proximal tubule (PT), and distal tubule (DT). Scale bar 20  $\mu$ M.